Home

Bay City Capital Fund V, L.P.

CIK 1401826 · last filed 2020-03-16

Bay City Capital Fund V, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for IMRA, was dated Mar 16, 2020. Across all open-market trades the lifetime net is −$39.2M, making them a net seller over the disclosed history. The firm reports its address in San Francisco, CA. 34 SEC filings were submitted jointly with BAY CITY CAPITAL LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

9

Lifetime Open-Market Net

-$39.17M

Filer Profile

Reported Address
750 Battery Street
Suite 400
San Francisco, CA 94111
Phone
(415) 676-3830
State of Incorporation
DE
Related Filers
BAY CITY CAPITAL LLC — 34 joint filings, latest 2020-03-16
Bay City Capital Fund V Co-Investment Fund, L.P. — 34 joint filings, latest 2020-03-16
Bay City Capital Management V LLC — 34 joint filings, latest 2020-03-16
CARL GOLDFISCHER — 1 joint filings, latest 2020-03-16
Bay City Capital Fund IV, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Enliven Therapeutics, Inc. (IMRA) Delisted 10%+ Owner 172,558 $14.59 $2.52M $0 1 2020-03-16
Viracta Therapeutics, Inc. (SNSS) Delisted 10%+ Owner 1,370,163 $18.62 $25.51M -$9.60M 1 2014-08-29
Epizyme, Inc. (EPZM) Delisted 10%+ Owner 2,829,136 $1.47 $4.16M -$28.11M 2 2014-08-28
HYPERION THERAPEUTICS INC (HPTX) Delisted 10%+ Owner 2,230,880 — — -$1.46M 5 2013-07-19

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-03-16 Enliven Therapeutics, Inc. (IMRA) Delisted Mixed +3,516,900 $0 EDGAR
2014-08-29 Viracta Therapeutics, Inc. (SNSS) Delisted Sell (S) −1,202,800 -$9.60M EDGAR
2014-08-28 Epizyme, Inc. (EPZM) Delisted Sell (S) −800,000 -$28.11M EDGAR
2014-08-28 Epizyme, Inc. (EPZM) Delisted — — $0 EDGAR
2013-07-19 HYPERION THERAPEUTICS INC (HPTX) Delisted Exer (X) −46,800 -$1.05M EDGAR
2013-07-19 HYPERION THERAPEUTICS INC (HPTX) Delisted Exer (X) −383,612 -$9.99M EDGAR
2013-05-31 HYPERION THERAPEUTICS INC (HPTX) Delisted Exer (X) +45,104 $211.6K EDGAR
2013-05-30 HYPERION THERAPEUTICS INC (HPTX) Delisted Sell (S) −69,464 -$1.46M EDGAR
2012-08-02 HYPERION THERAPEUTICS INC (HPTX) Delisted Mixed +9,811,576 $45.65M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.